Related Experiment Video
Updated: Jun 23, 2026
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients
Yongsheng Yu1, Hao Wu, Zhenghao Tang
1Department of Infectious Diseases, Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, China. yuyongsheng@medmail.com.cn
Abstract:
To determine whether RNA interference (RNAi) could block cytotoxic T-lymphocyte antigen 4 (CTLA4) in human lymphocytes in vitro and promote IFN-gamma and IL-2 secretions, three small interfering RNAs (siRNAs) were selected based on target specificity sequences of human CTLA4 and transfected into human lymphocytes of chronic HBV patients. As a result, the expression of human CTLA4 mRNA was efficiently suppressed by all the three siRNAs. Compared with negative control (siRNA-co), siRNA-1 inhibited the expression of CTLA4 most efficiently and was used in the further study. The expressions of IFN-gamma and IL-2 were upregulated and the level of IL-4 was almost unchanged in lymphocytes transfected with siRNA-1 compared with the blank control. These results indicated that siRNA-1 led to IFN-gamma and IL-2 secretions, which is a main response of Th1/Th2. In a conclusion, RNAi significantly suppressed the expression of human CTLA4 mRNA in human lymphocytes in vitro, and could induce Th1/Th2 response. It could be a new therapeutic strategy for chronic HBV infection.
Insights
RNA interference effectively silenced cytotoxic T-lymphocyte antigen 4 (CTLA4) in human lymphocytes, boosting immune responses. This approach shows promise as a novel therapeutic strategy for chronic hepatitis B virus (HBV) infection.
Area of Science:
- Immunology
- Molecular Biology
- Virology
Background:
- Chronic hepatitis B virus (HBV) infection is a global health concern.
- Cytotoxic T-lymphocyte antigen 4 (CTLA4) plays a role in immune regulation and can be a target for therapeutic intervention.
- Understanding immune responses in chronic HBV is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the efficacy of RNA interference (RNAi) in suppressing CTLA4 expression in human lymphocytes.
- To determine if blocking CTLA4 promotes the secretion of key cytokines, interferon-gamma (IFN-gamma) and interleukin-2 (IL-2).
- To evaluate the potential of RNAi targeting CTLA4 as a therapeutic strategy for chronic HBV infection.
Main Methods:
- Selection of three small interfering RNAs (siRNAs) targeting human CTLA4 based on sequence specificity.
- Transfection of selected siRNAs into human lymphocytes from patients with chronic HBV.
- Quantification of CTLA4 mRNA expression, IFN-gamma, IL-2, and IL-4 levels using molecular and immunological assays.
Main Results:
- All three siRNAs effectively suppressed human CTLA4 mRNA expression in vitro.
- siRNA-1 demonstrated the most potent inhibition of CTLA4 and was used for further analysis.
- Transfection with siRNA-1 led to significant upregulation of IFN-gamma and IL-2, indicative of a Th1/Th2 immune response, with minimal change in IL-4 levels.
Conclusions:
- RNAi is a viable method for significantly suppressing CTLA4 mRNA expression in human lymphocytes.
- Targeting CTLA4 with RNAi can induce a Th1/Th2 immune response, characterized by increased IFN-gamma and IL-2 secretion.
- This RNAi-mediated CTLA4 suppression presents a potential new therapeutic avenue for managing chronic HBV infection.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
